References
- Yale H. L., Sowinski F., Bernstein J. J. Am. Chem. Soc 1957; 79: 4375
- Piala J. J., Hassert G. L., High J. P., Burke J. C. Monographs on Therapy (The Squibb Institute for Medical Research) 1957; 2: 214
- Piala J. J., High J. P., Hassert G. L., Burke J. C., Craver B. N. J. Pharmacol. Exp. Ther 1959; 127: 55
- Yale H. L. J. Med. Pharm. Chem 1959; 1: 121
- Yale H. L., Sowinski F. J. Am. Chem. Soc 1960; 82: 2039
- High J. P., Hassert G. L., Rubin B., Piala J. J., Burke J. C., Craver B. N. Toxicol. Appl. Pharmacol 1960; 2: 540
- Junkmann K. Arch. Exp. Path. Pharmacol 1954; 244: 223
- Junkmann K., Witzel H. Monographs on Therapy (The Squibb Institute for Medical Research) 1958; 3: 3
- Kessler W. B., Borman A. Proc. Soc. Exp. Biol. Med. 1957; 94: 820, Ann. N. Y. Acad. Sci., 71, 486 (1958)
- Reifenstein E. C. Fertil. Steril 1957; 8: 50
- Ann. N. Y. Acad. Sci. 1958; 71: 762
- Yale H. L., Cohen A. I., Sowinski F. J. Med. Chem 1963; 6: 347
- Laffan R. J., High J. P., Burke J. C. Int. J. Neuropsychiatry 1961; 1: 300
- Ayd F. J. Am. J. Psychiatry 1975; 132: 491, A decade of clinical use of these two esters has been reviewed by, and by J. E. Groves and M. R. Mandel, Arch. Gen. Psychiatry, 32, 893 (1975). In England, over 400,000 chronic schizo-phrenics have been on maintenance therapy with these two drugs for many years; cf. S. R. Hirsch, R. Gaind, P. D. Rhode, B. C. Stevens, and J. K. Wing, Br. Med. J., 1, 633 (1973)
- Kiessling H., Elmqvist A. Acta Endocrinol 1960; 28: 502
- Dreyfuss J., Ross J. J., Shaw J. M., Miller I., Schreiber E. C. J. Pharm. Sci. 1976; 65: 502
- Dreyfuss J., Shaw J. M., Ross J. J. J. Pharm. Sci. 1976; 65: 1310
- Jorgensen A., Gottfries C. G. Psychophar-macologia 1972; 27: 1
- Sanseigne A. J., Yale H. L., Hess S. M., Burke J. C., Horovitz Z. P. Aggressologie 1968; 9: 3
- Ebert A. G., Yale H. L., Hess S. M. Fed. Proc 1963; 22: 539, Psychopharmacol Abstr., 3, 118 (1963); J. Pharmacol. Exp. Ther., 148, 412 (1965)
- Jilek J. O., Sindelar K., Dlabac A., Kazdova E., Pomykacek J., Sedivy Z., Protiva M. Collect. Czech. Chem. Commun 1973; 38: 1190, Among the products currently undergoing clinical investigation are Schering's perphenazine enanthate and decanoate, Rhone-Poulenc's pipotiazine undecylenate and palmitate, and Lund-beck's flupenthixol decanoate. In addition, Protiva and his group at the Research Institute for Pharmacy and Biochemistry in Prague have reported on the synthesis and activities of several long-chain esters of their tricycle, for the work of Protiva's group, as well as references to clinical studies with the above products]
- Whelpton R., Curry S. H. J. Pharm. Pharmacol 1976; 28: 869, These studies have most recently been reviewed by
- , Personal communication from Dr. F. J. Ayd
- Tenen S. S. Psychol. Sci. 1966; 6: 407
- Joulou L., Bourat G., Ducrot R., Fournel J., Garret E. Acta Psychiatr. Scand., Suppl 1973; 241: 9
- Joulou L., Bourat G., Ducrot R., Fournel J., Garret C., Mottet F. Therapie 1973; 28: 475
- Yale H. L. J. Med. Chem 1977; 20: 302
- Jilek J. O., Dlabac A., Protiva M. (1974) Conference on the Chemistry of Psychotropic Agents, Usti nad Labem. May 13–17, 1974
- Rapara R. T., Kraay R. J., Gerson K. J. Med. Chem 1965; 8: 580
- Ho B. T., Englert L. F., McKenna M. L. J. Med. Chem 1976; 19: 850
- French Patent 1,305,353. Chem. Abstr., 58, 9092 (1963)